Migraine Prevention Moves Into Focus With New Clinical Trials
Studies offer hope that CGRP antibodies will lead to better treatment for disabling headaches.
Read More
First Fully Human IL-17A Inhibitor Shows Sustained Efficacy, Safety Profile for Psoriasis Treatment
Positive 5-year efficacy and safety results shown for the interleukin-17A inhibitor.
FDA Expands Approval of CoreValve Evolut TAVR Platform
The FDA expanded approval of a self-expanding TAVR platform to include patients who are at an intermediate risk for open-heart surgery.
Empagliflozin Shows Benefits on Albuminuria
The EMPA-REG OUTCOME trial shows short- and long-term benefits of empagliflozin on albuminuria in patients with T2D and CVD.
Novo Nordisk Issues Voluntary Recall of Cartridge Holders in Some Insulin Delivery Devices
A small number of NovoPen Echo devices may crack or break if exposed to certain chemicals.
Results from SWITCH Trials Published
The drug reduced risk of overall symptomatic hypoglycemia compared to insulin glargine U100.
Children with PTSD Can Be Treated in Hours, Say Researchers in Amsterdam
Two therapies showed positive effect in less than 4 hours for treatment of children and adolescents with PTSD.
Incretin-Based Treatments: No Evidence of Rise in All-Cause Mortality for Patients with Type 2 Diabetes?
A meta-analysis provides no support for theory that incretin-based treatment causes increased mortality in patients with T2D.
Positive Phase 3 Results Announced for Eptinezumab Treatment of Frequent Episodic Migraine
Eptinezumab for frequent episodic migraine (EM) met primary and key secondary endpoints in the PROMISE 1 phase 3 trial.
Investigational Drug for Opioid Disorder Meets Primary and Secondary Endpoints in Phase 3 Trial
An investigational form of buprenorphine has been found to meet its primary and secondary endpoints in a phase 3 trial.
Fecal Microbes Remain 2 Years After Transplant to Treat Clostridium difficile
Certain microbial strains persisted in donor recipients for as long as 2 years after an FMT.
Prevention and Control Strategies for Clostridium difficile
An epidemiologist shares his knowledge about Clostridium difficile prevention and control.
Helping Youth with Type 1 Diabetes Improve Transition from Pediatric to Adult Care
Access to a transition coordinator benefited youths with T1D during their transition period.
Use of Lithium Carries Cardiac Risk to Developing Fetuses
Maternal use of lithium in the first trimester raises risk of cardiac defects to the fetus.
SGLT2 Inhibitors Associated with Lower Rates of Death, Hospitalization for Heart Failure in Patients with Type 2 Diabetes
Benefit was seen in 5 countries regardless of SGLT2 inhibitor used.
Single Dose of Glucagon Receptor Antibody Found to be as Effective in Reducing Insulin Need
Human antibody may substantially reduce need for insulin in patients with T1D.
CANVAS Results Show Significant Benefits for Cardiovascular and Kidney Disease
Results have major worldwide implications for type 2 diabetes treatment.
DEVOTE Trial Demonstrates Cardiovascular Safety and Reduces Risk of Severe Hypoglycemia
New-generation insulin found to have comparable cardiovascular safety to insulin glargine and significantly reduce episodes of severe hypoglycemia.
Results from inTandem1 and inTandem2 Unveiled at ADA 77th Scientific Sessions
Two pivotal studies on sotagliflozin were presented at the ADA’s 77th Scientific Sessions.
LixiLan-L Phase 3 Study Results Presented at ADA 77th Scientific Sessions
Insulin glargine 100 Units/mL and lixisenatide 33 mcg/mL combined lowered A1C levels by 1.09% to 2.41% after 30 weeks.
REMOVAL Trial Results Presented at ADA 77th Scientific Sessions
Metformin may reduce the risk of heart disease in adults with T1D.
ODYSSEY DM-DYSLIPIDEMIA Results Presented at ADA 77th Scientific Sessions
ODYSSEY DM-DYSLIPIDEMIA is 1 of 2 studies on alirocumab presented at ADA Scientific Sessions.
ODYSSEY DM-INSULIN Results Presented at ADA 77th Scientific Sessions
ODYSSEY DM-INSULIN is 1 of 2 studies on alirocumab presented at ADA Scientific Sessions.
Investigational SGLT-2 Inhibitor Meets Primary Endpoint in Phase 3 Studies
Merck and Pfizer have announced that VERTIS MET and VERTIS SITA met primary endpoints.
DELIVER 3 Results Presented at ADA 77th Scientific Sessions
Patients who switched to insulin glargine 300 Units/mL were 57% less likely to experience hypoglycemia at 6-months.
Teens with Type 1 Diabetes Can Text Message Improved Glycemic Control
Teens with T1D improved their A1C levels by frequent 2-way texting.
Severely Obese Children Have Dangerously Increased Risk of Type 2 Diabetes
Severely obese American Indian children had a 12-times higher risk of developing T2D as normal-weight youth.
Overweight Boys Have Chance to Avoid Type 2 Diabetes
Boys who are overweight as children but normalize as young adults have the same risk of type 2 diabetes as men who were never overweight.
ADA 77th Scientific Sessions Packed with Clinical Trial Results
More than 3,000 original research presentations will be offered in a robust 5-day program.
Racial and Ethnic Differences in Access to Care Studied
Associations between race/ethnicity and lack of in healthcare access were found.